Healthcare Services

Liquid Biopsy Market Growth Trends and Forecast Through 2030

April 23, 2026April 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Liquid Biopsy Market From 2026 To 2030?

The liquid biopsy market has shown significant expansion in recent years. It is projected to grow from $1.46 billion in 2025 to $1.71 billion in 2026, with a compound annual growth rate (CAGR) of 17.3%. This historical development can be attributed to various factors, including the limitations inherent in traditional tissue biopsy methods, a rising global prevalence of cancer, the prompt adoption of blood-based diagnostics, advancements made in molecular biology techniques, and a heightened focus on the early detection of cancer.

The liquid biopsy market is projected for significant expansion over the coming years. Its value is estimated to reach $3.11 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.2%. This anticipated growth during the forecast period stems from factors such as heightened demand for precision oncology, wider incorporation into routine cancer screening, broader uses in recurrence monitoring, an increase in oncology diagnostic expenditures, and growing recognition among healthcare professionals and patients. Key trends shaping the forecast period encompass the increasing embrace of non-invasive cancer diagnostics, the expanded application of liquid biopsy for early cancer identification, a heightened need for real-time treatment oversight, the broadening role of liquid biopsy in personalized oncology, and its increasing clinical approval as a substitute for tissue biopsy.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

What Leading Drivers Are Supporting The Liquid Biopsy Market Expansion?

The expansion of the liquid biopsy market is significantly propelled by an increase in government funding dedicated to advancing cancer detection. This public investment in enhanced cancer detection methods primarily stems from the escalating worldwide prevalence of cancer, the necessity for early diagnosis to improve patient outcomes, and the focus on reducing healthcare expenditures through innovative diagnostic technologies. Government financial support benefits liquid biopsy by expediting research and development, backing clinical trials, and fostering the wider adoption of advanced, non-invasive diagnostic tools, thereby enhancing early cancer identification and personalized treatment strategies. For instance, in October 2024, gov.UK, a UK-based government website, announced that UK Research and Innovation received a total allocation of £118 ($150.38) million, comprising £54 million from the government and £64 ($81.55) million from partners. Consequently, the rising government funding for the progression of cancer detection is indeed fueling the growth of the liquid biopsy market.

How Are Segments Identified Within The Liquid Biopsy Market Segment Framework?

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

What Emerging Trends Are Seen In The Liquid Biopsy Market?

Companies operating in the liquid biopsy market are prioritizing the development of novel solutions, including comprehensive circulating tumor DNA (ctDNA) genomic-profiling assays. These initiatives aim to expedite noninvasive cancer profiling, enable more rapid therapeutic decision-making, and broaden access to precision oncology in situations where tissue is limited or cannot be obtained. Such an assay operates by analyzing tumor-derived cell-free DNA fragments found in blood, detecting somatic small variants, copy-number changes, insertions/deletions, and immuno-oncology signatures (e.g., bTMB and bMSI). This method provides broader tumor insight, bypassing the invasiveness, sampling bias, and longer turnaround time typical of conventional tissue biopsies. For example, in November 2023, Illumina Inc., a US-based sequencing and genomics company, unveiled TruSight Oncology 500 ctDNA v2. This research-use liquid biopsy panel is designed for noninvasive genomic profiling of solid tumors, featuring an expanded hybrid-capture panel integrated with DRAGEN bioinformatics for sequencing 523 biomarkers from low cfDNA input. This assay is capable of enriching and detecting SVs, CNVs, indels, and immuno-oncology metrics with high analytical performance. It provides streamlined workflows, including a single hybridization step and a turnaround time of less than 4 days, while being compatible with NovaSeq systems and upcoming automation. The solution supports applications when tissue is unavailable or delayed, complements tissue testing, and enables broad pan-cancer research and trial screening. It offers benefits such as faster insights, suitability for low-input samples, and easier adoption across distributed lab environments.

Who Are The Companies Competing Within The Liquid Biopsy Market?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Get The Full Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Which Region Represents The Largest Share Of The Liquid Biopsy Market?

North America was the largest region in the liquid biopsy market in 2025. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Liquid Biopsy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Browse Through More Reports Similar to the Global Liquid Biopsy Market 2026, By The Business Research Company

Liquid Biopsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Biopsy Devices Market Report

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Cancer Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795